ZYVERSA THERAPEUTICS INC (ZVSA) Stock Income Statement
NASDAQ:ZVSA - Nasdaq - US98987D3008 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 8.45M | 9.14M | 14.42M | 13.83M | 7.70M | |||
| Research and Development | 1.53M | 1.78M | 3.21M | 5.81M | 2.12M | |||
| Selling, General, and Administrative Expenses | 6.93M | 7.35M | 11.20M | 8.02M | 5.57M | |||
| Operating Income | -8.45M | -9.14M | -14.42M | -13.83M | -7.70M | |||
| Interest Income/Expense | -389.40K | -269.90K | 500.00 | -1.03M | -593.30K | |||
| Non Recurring Items | N/A | N/A | -93.33M | 0.00 | 213.50K | |||
| Income Before Taxes | -8.84M | -9.41M | -107.75M | -14.87M | -8.08M | |||
| Income Tax | N/A | 6.80K | -9.46M | -745.00K | 0.00 | |||
| Net Income | -8.84M | -9.41M | -106.25M | -24.14M | -8.08M | |||
| EBITDA | N/A | -9.13M | -14.41M | -13.82M | -7.69M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -7.18 | -8.48 | -1.09K | -917.81 | -307.38 | |||
| Statistics | ||||||||
All data in USD